Avalo Therapeutics (AVTX) EBITDA (2014 - 2025)
Avalo Therapeutics (AVTX) EBITDA from Sep 30, 2014 to Dec 31, 2025. The TTM Avalo Therapeutics (AVTX) EBITDA is -$73M. You can adjust inflation or export chart.
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
Annual EBITDA
Quarterly EBITDA
Avalo Therapeutics (AVTX) EBITDA CAGR table
| Period | CAGR |
|---|---|
| 3 Years TTM | +24.87% |
| 5 Years TTM | +0.44% |
| 10 Years TTM | +20.79% |
| All Time TTM | +27.77% |
Annual EBITDA change of Avalo Therapeutics (AVTX)
| Year | EBITDA | Change |
|---|---|---|
| 2025 | -$73M | +6.20% |
| 2024 | -$68M | +151.34% |
| 2023 | -$27M | -27.05% |
| 2022 | -$37M | -53.69% |
| 2021 | -$80M | +13.35% |
| 2020 | -$71M | +479.59% |
| 2019 | -$12M | -60.25% |
| 2018 | -$31M | -315.22% |
| 2017 | $14M | -189.22% |
| 2016 | -$16M | +46.04% |
| 2015 | -$11M | -35.69% |
| 2014 | -$17M | +32.38% |
| 2013 | -$13M | N/A |
Comparison Avalo Therapeutics (AVTX) five years EBITDA CAGR with competitors
Avalo Therapeutics (AVTX) five years EBITDA CAGR is 9.14%.